U.S. Auto Stock News

Corteva (CTVA) just teamed up with Hexagon Bio in a multi million dollar joint venture that leans hard into nature inspired, AI driven crop protection, a move that also nudges Corteva toward human health applications. See our latest analysis for Corteva. That backdrop helps explain why investors have quietly rewarded Corteva, with a roughly 19.5 percent year to date share price return and an 18.3 percent one year total shareholder return signaling steady, rather than explosive, momentum as...

T1 Energy, headquartered in Austin, just paired a three year, 900MW supply deal with Treaty Oak Clean Energy with construction on its G2_Austin cell fab, and the market noticed. Let us unpack why. See our latest analysis for T1 Energy. That Treaty Oak contract and the G2_Austin build out help explain why the 30 day share price return has surged 124.52 percent and year to date share price momentum of 158.24 percent contrasts with a still negative 5 year total shareholder return. This suggests...

AST SpaceMobile has now successfully launched its BlueBird 6 satellite into low Earth orbit, deploying what it describes as the largest commercial communications array designed to deliver 4G and 5G broadband directly to standard, unmodified smartphones. This marks a shift from years of development to the early stages of network deployment, with plans for dozens more satellites and commercial agreements covering nearly 3 billion mobile subscribers worldwide. We’ll now look at how the BlueBird...

Wondering whether Rivian Automotive is still a speculative story or actually starting to look like a genuine value opportunity? You are not alone; many investors are trying to figure out if the current price makes sense. After a volatile ride, Rivian's share price has surged 19.9% over the last week, 39.3% over the past month, and 59.5% year to date, with a 50.3% gain over the last year that signals a serious shift in sentiment. That renewed optimism has been fueled by steady progress on...

A wave of securities class actions has put Synopsys (SNPS) under the microscope, as multiple law firms allege the company understated how its pivot toward AI customers was pressuring the economics of its Design IP business. See our latest analysis for Synopsys. The legal overhang is arriving just as sentiment around Synopsys had started to thaw, with a roughly 17.6 percent 1 month share price return lifting the stock back to about $475.75. However, the 1 year total shareholder return remains...

Novo Nordisk (NYSE:NVO) has been on a choppy ride lately, with the stock rebounding over the past month after a weaker stretch in the past 3 months and year to date. See our latest analysis for Novo Nordisk. That rebound stands out against a much softer backdrop, with a 30 day share price return of 16.88 percent offsetting a weak year to date share price performance and a negative one year total shareholder return. This hints that sentiment may be stabilising after a sharp reset. If Novo...

If you are wondering whether Baidu is still a bargain after its recent run, or if you have already missed the upside, this breakdown will walk through what the current price is actually implying about its future. After a strong rebound with shares up 3.2% over the last week, 3.5% over the past month, and a 49.2% gain year to date, investors are clearly rethinking Baidu's prospects despite a still negative 43.8% return over five years. Recent headlines have focused on Baidu's push to...

Analog Devices (ADI) just checked several important boxes for investors at once, with a strong fiscal Q4, upbeat guidance, and planned 2026 price hikes that together point to firmer demand and healthier margins. See our latest analysis for Analog Devices. The market seems to be catching on to that story, with a roughly 16 percent 1 month share price return helping lift the stock to about 31 percent year to date. A 5 year total shareholder return above 100 percent points to momentum that has...

DaVita (DVA) has quietly slipped over the past month, extending a tougher stretch this year, and that kind of pullback naturally raises the question: has the market become too pessimistic here? See our latest analysis for DaVita. The recent slide fits into a wider reset, with the 1-year total shareholder return down sharply even after a strong three-year total shareholder return. This suggests momentum has clearly cooled as investors reassess growth and reimbursement risk at a share price of...

If you have been wondering whether Alliance Resource Partners is still a good value pick after its huge multi year run, this breakdown will walk through what the current price is really baking in. The stock has pulled back about 11.0% year to date and is roughly flat over the last month, but it is still up 64.6% over three years and an eye catching 744.1% over five years. That kind of long term outperformance has come as investors reassessed the outlook for coal linked cash flows and the...

NRG Energy (NRG) has quietly turned into one of the market’s more interesting utility stories, with the stock up 73% this year even after a modest pullback over the past month. See our latest analysis for NRG Energy. At a current share price of $160.56, NRG’s strong year to date share price return contrasts with a softer recent patch. Yet a 1 year total shareholder return near 75% and an exceptional multi year total shareholder return signal that momentum in the story is still very much...

Sprouts Farmers Market is now facing multiple securities fraud class action lawsuits alleging that management made false or misleading statements about 2025 growth prospects, customer resilience to macroeconomic pressures, and comparable-store performance prior to cutting full-year guidance after a weaker third quarter. The clustering of law firm investigations and class actions highlights heightened legal and disclosure risk for Sprouts, centering on whether prior growth commentary...

Recent performance and why investors are watching Coinbase Global (COIN) has been sliding over the past month, with the stock down about 6% and roughly 22% in the past 3 months, even as revenue continues to grow modestly. See our latest analysis for Coinbase Global. Stepping back, the recent 30 day share price pullback fits into a choppier year for Coinbase Global, with share price returns softening even as its three year total shareholder return remains exceptionally strong. This suggests...

If you are wondering whether Union Pacific at around $235 a share is quietly becoming good value, or if the easy money has already been made, this breakdown will help you decide whether the stock still deserves a place on your radar. Despite some recent volatility, the stock is up 4.7% over the last month and 4.7% over the past year. Longer term returns of 21.9% over 3 years and 27.6% over 5 years show it has rewarded patient shareholders. Recently, the market has been digesting a mix of...

Roblox (RBLX) is under the microscope right now, with fresh child safety lawsuits and regulatory scrutiny colliding with heavy spending on AI safety, infrastructure, and creator payouts. That mix is driving the latest slide in the stock. See our latest analysis for Roblox. Those headline grabbing lawsuits and the Russia related restrictions are landing just as Roblox leans into new partnerships like its Universal Music Group deal, and the tension is showing up in the numbers. A roughly 38% 3...

Limoneira (LMNR) just posted its FY 2025 fourth quarter results with revenue of about $42.8 million and a basic EPS loss of roughly $0.49, capping off a year in which trailing twelve month revenue came in at around $159.7 million and EPS landed at about negative $0.92. Over the past six quarters, the company has seen quarterly revenue move between roughly $34.3 million and $63.3 million while EPS has swung from a profit of about $0.36 per share to losses such as the latest print. This sets up...

Mirum Pharmaceuticals (MIRM) has quietly rewarded patient investors, with the stock up roughly 9% over the past month and more than 90% this year. This invites a closer look at what the market is pricing in. See our latest analysis for Mirum Pharmaceuticals. That surge is not a one off. The 30 day share price return of 11.84 percent and year to date share price gain of 92.08 percent sit on top of a 3 year total shareholder return above 340 percent. This suggests momentum is still firmly with...

Earlier this month, DraftKings launched DraftKings Predictions, a CFTC-regulated standalone app and web platform that lets eligible U.S. customers trade event contracts on sports and financial outcomes across 38 states, with more categories expected over time. This move pushes DraftKings into federally regulated prediction markets through a CFTC-registered Introducing Broker subsidiary, broadening its addressable market beyond traditional sports betting and iGaming. Next, we’ll examine how...

On December 9, 2025, H.C. Wainwright analyst Patrick Trucchio reaffirmed a positive view on Beam Therapeutics after reviewing encouraging BEACON trial data indicating that risto-cel may offer an innovative treatment option for sickle cell disease. The analyst also highlighted Beam’s differentiated and scalable manufacturing process for risto-cel, suggesting a potential competitive edge in ex vivo hematology gene-editing therapies. Next, we’ll examine how this encouraging BEACON trial data,...

Verisk Analytics (VRSK) is drawing fresh attention after expanding its partnership with KYND to plug richer cyber risk intelligence directly into its Rulebook platform, just as UK retail cyber vulnerabilities are coming into sharper focus. See our latest analysis for Verisk Analytics. Even with this cyber push, Verisk’s recent share price return has been weak. The stock is now at $218.85 and momentum is fading in the near term, though the three year total shareholder return of 28.01% still...

Phillips 66 and Kinder Morgan recently reported that the initial open season for their proposed Western Gateway refined products pipeline system has closed after attracting strong shipper commitments linking Borger, Texas to Phoenix, Arizona and, via reversed SFPP assets, into key California markets. The project’s use of joint tariffs, pipeline reversals and connections to assets like Kinder Morgan’s CALNEV line could reshape refined product flows from Midwest refineries to Phoenix, Los...

If you are wondering whether USA Rare Earth is actually worth the buzz at its current price, or if the value story is getting ahead of itself, you are not alone. The stock has climbed 7.2% in the last week and 17.5% over the past month, with a 32.7% gain over the last year. This signals that investors are starting to price in more upside and possibly a bit more risk as well. Recent coverage around the US critical minerals strategy and supply chain security has put companies like USA Rare...

If you are wondering whether International Business Machines is still a value play after its significant share price increase, or if you may have missed the opportunity, this breakdown will help you assess whether IBM deserves a place in your portfolio right now. IBM's share price has climbed to around $304.56, with returns of 0.4% over the last week, 0.1% over the last month, 38.5% year to date, 39.2% over 1 year, 142.7% over 3 years, and 215.4% over 5 years. These figures naturally raise...

Bristol Myers Squibb (BMY) has been back on investors radar after the FDA cleared Breyanzi as the first CAR T therapy for relapsed or refractory marginal zone lymphoma, reinforcing the company presence in B cell malignancies. See our latest analysis for Bristol-Myers Squibb. The latest Breyanzi approval lands at a moment when sentiment is already shifting, with a 30 day share price return of 14.55% and a 90 day share price return of 26.03% from $54.71, even though the 1 year total shareholder...